INTRODUCTION AND OBJECTIVES: Current treatments for cystinuria have limited effectiveness as well as short and long-term side effects. Dilutional therapy reduces recurrence, but many patients have difficulty maintaining high fluid intake. The vasopressin V2-receptor antagonist tolvaptan increases urinary excretion of free water. We sought to perform a pilot study of short-term safety, tolerability, and impact of oral tolvaptan on urinary stone risk parameters. METHODS: We enrolled cystinuria patients age 12-25 yrs. Subjects were treated for 4 days at lower dose (0.3 mg/kg daily, up to 30 mg) and 4 days at higher dose (0.6 mg/kg daily, up to 60 mg). Subjects were closely monitored throughout the study period. 24 hour urine collections were done at baseline, at day 3-4 of the dosing period, at day 7-8 of the dosing period, and 3-6 days after washout. Primary outcome was cystine capacity (mg/L), a measure of supersaturation unaffected by concurrent treatment with sulfhydryl drugs. Target capacity is a positive value. Secondary outcomes included other urinary/ serum parameters, tolerability, and thirst response. Subjects continued their home medical regimen (including tiopronin) during the study period.
RESULTS: 2 females (17, 23 yrs) and 2 males (13, 24 yrs) were enrolled. Cystine capacity respectively went from baseline of -312, -82, -353 and -628 mg/L to 97, 111, 75 and -3 mg/L on high dose (Figure 1 ). 24-hour volume went from 1.96, 3.0, 2.1 and 0.91 L to 11.74, 6.5, 9.9 and 2.8 L on high dose (Figure 2 ). There were no abnormalities in serum electrolytes or liver enzymes during the treatment period. Subjects did experience severe thirst, with thirst rated 9/10 on a visual analog scale, but all completed treatment and none terminated or reduced dose.
CONCLUSIONS: Dilutional therapy with tolvaptan increased both cystine capacity and urinary volumes. This treatment approach has the potential to reduce recurrence of stones in this population. Further investigation should study longer term effects and safety, and determine optimal dosing to improve tolerability.
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MP12-05 UTILIZATION OF A SMART WATER BOTTLE TO INCREASE FLUID INTAKE IN STONE FORMERS
Thomas Stout*, Minneapolis, MN; James Lingeman, Amy Krambeck, Indianapolis, IN; Mitchell Humphreys, Scottsdale, AZ; Anna Zisman, Chicago, IL; Sarah Elfering, Michael Borofsky, Minneapolis, MN INTRODUCTION AND OBJECTIVES: High dietary fluid intake is a cornerstone of kidney stone prevention; yet, is challenging to achieve. There is interest in using smart water bottles for this purpose but sparse data exists as to whether such technology leads to better outcomes relative to standard counseling. We sought to assess whether the addition of a smart water bottle to standard dietary fluid recommendations leads to improved urine volume.
METHODS: IRB approval was obtained to offer voluntary enrollment into a prospective randomized controlled trial comparing the effect of standard dietary fluid recommendations (DR) to standard DR with addition of a smart water bottle (SB) on 24 hour urine (24 hr U) volume. Eligible participants included those over age 18 with a history of nephrolithiasis and low urine volume (<1.5L) in the past 6 months. All subjects received a handout with strategies to achieve a goal urine output of 2.5 L/day. The intervention arm also received a smart water bottle (HidrateSpark, Minneapolis MN) with a sensor that recorded daily fluid intake, synced to the user's smartphone, and provided periodic reminders to drink. All patients completed a baseline survey to assess
